{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T04:05:24Z","timestamp":1791518724310,"version":"4.3.4"},"reference-count":47,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,6,18]],"date-time":"2025-06-18T00:00:00Z","timestamp":1750204800000},"content-version":"am","delay-in-days":321,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100000049","name":"National Institute on Aging","doi-asserted-by":"publisher","award":["P30AG024832"],"award-info":[{"award-number":["P30AG024832"]}],"id":[{"id":"10.13039\/100000049","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000026","name":"National Institute on Drug Abuse","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000026","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.com.au","clinicalkey.es","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Preventive Medicine"],"published-print":{"date-parts":[[2024,8]]},"DOI":"10.1016\/j.ypmed.2024.108046","type":"journal-article","created":{"date-parts":[[2024,6,17]],"date-time":"2024-06-17T19:14:30Z","timestamp":1718651670000},"page":"108046","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"special_numbering":"C","title":["Patterns of gabapentinoid use among long-term opioid users"],"prefix":"10.1016","volume":"185","author":[{"given":"Jordan","family":"Westra","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mukaila","family":"Raji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacques","family":"Baillargeon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rajender R.","family":"Aparasu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yong-Fang","family":"Kuo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ypmed.2024.108046_bb0005","first-page":"27","article-title":"Trends in gabapentinoid prescribing in UK primary care using the clinical practice Research datalink: an observational study","author":"Ashworth","year":"2023","journal-title":"Lancet Reg Health \u2013 Eur."},{"issue":"7","key":"10.1016\/j.ypmed.2024.108046_bb0010","doi-asserted-by":"crossref","first-page":"1499","DOI":"10.1097\/j.pain.0000000000000554","article-title":"A randomized controlled trial of gabapentin for chronic low back pain with and without a radiating component","volume":"157","author":"Atkinson","year":"2016","journal-title":"Pain"},{"issue":"3","key":"10.1016\/j.ypmed.2024.108046_bb0015","article-title":"A review of potential adverse effects of long-term opioid therapy: a practitioner\u2019s guide","volume":"14","author":"Baldini","year":"2012","journal-title":"Prim Care Compan. CNS Disord."},{"key":"10.1016\/j.ypmed.2024.108046_bb0020","doi-asserted-by":"crossref","DOI":"10.1016\/j.drugalcdep.2020.108248","article-title":"The association between opioid discontinuation and heroin use: a nested case-control study","volume":"217","author":"Binswanger","year":"2020","journal-title":"Drug Alcohol Depend."},{"issue":"12","key":"10.1016\/j.ypmed.2024.108046_bb0025","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1016\/j.euroneuro.2017.08.430","article-title":"How addictive are gabapentin and pregabalin? A systematic review","volume":"27","author":"Bonnet","year":"2017","journal-title":"Eur. Neuropsychopharmacol."},{"key":"10.1016\/j.ypmed.2024.108046_bb0030","article-title":"Gabapentinoid use by self-reported indication and level of evidence","volume":"4","author":"Chaitoff","year":"2023","journal-title":"J. Gen. Intern. Med."},{"issue":"1","key":"10.1016\/j.ypmed.2024.108046_bb0035","doi-asserted-by":"crossref","first-page":"5005","DOI":"10.1038\/s41467-023-40637-8","article-title":"Gabapentinoid consumption in 65 countries and regions from 2008 to 2018: a longitudinal trend study","volume":"14","author":"Chan","year":"2023","journal-title":"Nat. Commun."},{"issue":"2","key":"10.1016\/j.ypmed.2024.108046_bb0040","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1177\/2049463720912496","article-title":"Gabapentinoids: pharmacokinetics, pharmacodynamics and considerations for clinical practice","volume":"14","author":"Chincholkar","year":"2020","journal-title":"Br. J. Pain"},{"key":"10.1016\/j.ypmed.2024.108046_bb0045","article-title":"The effectiveness and risks of long-term opioid treatment of chronic pain","author":"Chou","year":"2014","journal-title":"Agenc. Healthc. Res. Qualit."},{"key":"10.1016\/j.ypmed.2024.108046_bb0050","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.g1251","article-title":"Rates and risk factors for prolonged opioid use after major surgery: population based cohort study","volume":"348","author":"Clarke","year":"2014","journal-title":"BMJ"},{"issue":"36","key":"10.1016\/j.ypmed.2024.108046_bb0055","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.15585\/mmwr.mm6736a2","article-title":"Prevalence of chronic pain and high-impact chronic pain among adults - United States, 2016","volume":"67","author":"Dahlhamer","year":"2018","journal-title":"MMWR Morb. Mortal Wkly. Rep."},{"key":"10.1016\/j.ypmed.2024.108046_bb0060","series-title":"Office of Diversion Control, Drug & Chemical Evaluation Section. Hydrocodone (Trade Names: Vicodin\u00ae, Lortab\u00ae, Lorcet-HD\u00ae, Hycodan\u00ae, Vicoprofen\u00ae)","author":"Department of Justice, Drug Enforcement Administration","year":"2014"},{"key":"10.1016\/j.ypmed.2024.108046_bb0065","first-page":"71","article-title":"CDC clinical practice guideline for prescribing opioids for pain \u2014 United States, 2022","author":"Dowell","year":"2022","journal-title":"MMWR Recomm. Rep."},{"key":"10.1016\/j.ypmed.2024.108046_bb0070","first-page":"65","article-title":"CDC guideline for prescribing opioids for chronic pain \u2014 United States, 2016","author":"Dowell","year":"2016","journal-title":"MMWR Recomm. Rep."},{"issue":"163","key":"10.1016\/j.ypmed.2024.108046_bb0075","first-page":"49661","article-title":"Schedules of controlled substances: rescheduling of hydrocodone combination products from schedule III to schedule II. Final rule","volume":"79","author":"Drug Enforcement Administration, Department of Justice","year":"2014","journal-title":"Fed. Regist."},{"issue":"11","key":"10.1016\/j.ypmed.2024.108046_bb0080","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2021-053487","article-title":"Trends in prescribing pattern of opioid and benzodiazepine substitutes among Medicare part D beneficiaries from 2013 to 2018: a retrospective study","volume":"11","author":"Esechie","year":"2021","journal-title":"BMJ Open"},{"key":"10.1016\/j.ypmed.2024.108046_bb0085","first-page":"1","article-title":"Examining racial\/ethnic differences in patterns of opioid prescribing: results from an urban safety-net healthcare system","author":"Flores","year":"2023","journal-title":"J. Racial Ethn. Health Disparities"},{"key":"10.1016\/j.ypmed.2024.108046_bb0090","doi-asserted-by":"crossref","first-page":"1105681","DOI":"10.3389\/fpubh.2023.1105681","article-title":"The effect of the COVID-19 pandemic on the prescribing of opioid and opioid use disorder medications within an academic medical center in California","volume":"11","author":"Fstkchian","year":"2023","journal-title":"Front. Public Health"},{"issue":"5","key":"10.1016\/j.ypmed.2024.108046_bb0095","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1056\/NEJMp1704633","article-title":"Gabapentin and Pregabalin for pain \u2014 is increased prescribing a cause for concern?","volume":"377","author":"Goodman","year":"2017","journal-title":"N. Engl. J. Med."},{"issue":"5","key":"10.1016\/j.ypmed.2024.108046_bb0100","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1001\/jamainternmed.2019.0086","article-title":"A clinical overview of off-label use of Gabapentinoid drugs","volume":"179","author":"Goodman","year":"2019","journal-title":"JAMA Intern. Med."},{"key":"10.1016\/j.ypmed.2024.108046_bb0105","first-page":"2022","article-title":"Trends in Prescriptions for Non-opioid Pain Medications Among U.S. Adults With Moderate or Severe Pain","volume":"8","author":"Gorfinkel","year":"2014","journal-title":"J. Pain"},{"issue":"26","key":"10.1016\/j.ypmed.2024.108046_bb0110","doi-asserted-by":"crossref","first-page":"697","DOI":"10.15585\/mmwr.mm6626a4","article-title":"Vital signs: changes in opioid prescribing in the United States, 2006\u20132015","volume":"66","author":"Guy","year":"2017","journal-title":"MMWR Morb. Mortal Wkly. Rep."},{"issue":"4","key":"10.1016\/j.ypmed.2024.108046_bb0115","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1016\/j.ocl.2023.05.002","article-title":"Modern perioperative pain management strategies to minimize opioids after Total knee arthroplasty","volume":"54","author":"Hansen","year":"2023","journal-title":"Orthop. Clin. North Am."},{"issue":"3","key":"10.1016\/j.ypmed.2024.108046_bb0120","article-title":"Prescription analgesic medication use among osteoarthritis patients","volume":"31","author":"Huang","year":"2023","journal-title":"J. Orthop. Surg. Hong Kong."},{"issue":"11","key":"10.1016\/j.ypmed.2024.108046_bb0125","doi-asserted-by":"crossref","first-page":"1230","DOI":"10.1016\/j.jpain.2010.07.002","article-title":"The prevalence of chronic pain in United States adults: results of an internet-based survey","volume":"11","author":"Johannes","year":"2010","journal-title":"J. Pain"},{"issue":"7","key":"10.1016\/j.ypmed.2024.108046_bb0130","doi-asserted-by":"crossref","first-page":"980","DOI":"10.1093\/gerona\/glx229","article-title":"Measuring frailty in Medicare data: development and validation of a claims-based frailty index","volume":"73","author":"Kim","year":"2018","journal-title":"J. Gerontol. A Biol. Sci. Med. Sci."},{"issue":"4","key":"10.1016\/j.ypmed.2024.108046_bb0135","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1001411","article-title":"Untreated pain, narcotics regulation, and Global Health ideologies","volume":"10","author":"King","year":"2013","journal-title":"PLoS Med."},{"key":"10.1016\/j.ypmed.2024.108046_bb0140","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/j.neuroscience.2016.06.057","article-title":"Antidepressants and gabapentinoids in neuropathic pain: mechanistic insights","volume":"338","author":"Kremer","year":"2016","journal-title":"Neuroscience"},{"issue":"5","key":"10.1016\/j.ypmed.2024.108046_bb0145","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1111\/jgs.15332","article-title":"Opioid prescriptions in older Medicare beneficiaries after the 2014 Federal Rescheduling of hydrocodone products","volume":"66","author":"Kuo","year":"2018","journal-title":"J. Am. Geriatr. Soc."},{"key":"10.1016\/j.ypmed.2024.108046_bb0150","article-title":"Pregabalin and gabapentin for pain","volume":"369","author":"Mathieson","year":"2020","journal-title":"BMJ"},{"issue":"3","key":"10.1016\/j.ypmed.2024.108046_bb0155","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1111\/j.1532-5415.2011.03318.x","article-title":"Opioid analgesics and the risk of fractures among older adults with arthritis","volume":"59","author":"Miller","year":"2011","journal-title":"J. Am. Geriatr. Soc."},{"issue":"4","key":"10.1016\/j.ypmed.2024.108046_bb0160","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1056\/NEJMsa2034159","article-title":"Racial inequality in prescription opioid receipt \u2014 role of individual health systems","volume":"385","author":"Morden","year":"2021","journal-title":"N. Engl. J. Med."},{"issue":"6","key":"10.1016\/j.ypmed.2024.108046_bb0165","first-page":"589","article-title":"Associations between chronic pain, anxiety, and depression among adults in the United States","volume":"23","author":"Mullins","year":"2023","journal-title":"Pain Pract. Off. J. World Inst. Pain."},{"key":"10.1016\/j.ypmed.2024.108046_bb0170","series-title":"Prescription Opioid Use among Adults with Chronic Pain: United States, 2019","author":"National Center for Health Statistics (U.S.)","year":"2021"},{"key":"10.1016\/j.ypmed.2024.108046_bb0175","article-title":"Opioid utilization in geriatric patients after operation for degenerative spine disease","volume":"21","author":"Nguyen","year":"2020","journal-title":"J. Neurosurg. Anesthesiol."},{"key":"10.1016\/j.ypmed.2024.108046_bb0180","article-title":"Associations between stopping prescriptions for opioids, length of opioid treatment, and overdose or suicide deaths in US veterans: observational evaluation","volume":"368","author":"Oliva","year":"2020","journal-title":"BMJ"},{"issue":"2","key":"10.1016\/j.ypmed.2024.108046_bb0185","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1016\/j.jpain.2018.07.006","article-title":"Prevalence and profile of high-impact chronic pain in the United States","volume":"20","author":"Pitcher","year":"2019","journal-title":"J. Pain"},{"key":"10.1016\/j.ypmed.2024.108046_bb0190","series-title":"Products - Data Briefs - Number 457 - December","year":"2022"},{"issue":"6","key":"10.1016\/j.ypmed.2024.108046_bb0195","doi-asserted-by":"crossref","first-page":"1174","DOI":"10.1111\/jgs.15779","article-title":"Tricyclic antidepressant and\/or \u03b3-aminobutyric acid-analog use is associated with fall risk in diabetic peripheral neuropathy","volume":"67","author":"Randolph","year":"2019","journal-title":"J. Am. Geriatr. Soc."},{"key":"10.1016\/j.ypmed.2024.108046_bb0200","series-title":"Warns About Serious Breathing Problems with Seizure and Nerve Pain Medicines Gabapentin (Neurontin, Gralise, Horizant) and Pregabalin (Lyrica, Lyrica CR)","author":"Research C for DE and. FDA","year":"2020"},{"issue":"12","key":"10.1016\/j.ypmed.2024.108046_bb0205","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2021-052057","article-title":"Association of co-prescribing of opioid and benzodiazepine substitutes with incident falls and fractures among older adults: a cohort study","volume":"11","author":"Shah","year":"2021","journal-title":"BMJ Open"},{"issue":"8","key":"10.1016\/j.ypmed.2024.108046_bb0210","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1002369","article-title":"Benefits and safety of gabapentinoids in chronic low back pain: a systematic review and meta-analysis of randomized controlled trials","volume":"14","author":"Shanthanna","year":"2017","journal-title":"PLoS Med."},{"key":"10.1016\/j.ypmed.2024.108046_bb0215","series-title":"Status of State Action on the Medicaid Expansion Decision","year":"2021"},{"key":"10.1016\/j.ypmed.2024.108046_bb0220","series-title":"The Prescribing Patterns of Gabapentin and Pregabalin in a Medicaid Population Amid the Opioid Epidemic","volume":"1","author":"Sullivan","year":"2019"},{"issue":"6","key":"10.1016\/j.ypmed.2024.108046_bb0225","article-title":"Gabapentin for chronic neuropathic pain in adults","volume":"2017","author":"Wiffen","year":"2017","journal-title":"Cochrane Database Syst. Rev."},{"key":"10.1016\/j.ypmed.2024.108046_bb0230","series-title":"StatPearls","article-title":"Gabapentin","author":"Yasaei","year":"2022"},{"issue":"2","key":"10.1016\/j.ypmed.2024.108046_bb0235","doi-asserted-by":"crossref","DOI":"10.1097\/j.pain.0000000000002291","article-title":"Prevalence of chronic pain among adults in the United States","volume":"163","author":"Yong","year":"2022","journal-title":"PAIN"}],"container-title":["Preventive Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0091743524002019?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0091743524002019?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,9,27]],"date-time":"2024-09-27T14:59:23Z","timestamp":1727449163000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0091743524002019"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8]]},"references-count":47,"alternative-id":["S0091743524002019"],"URL":"https:\/\/doi.org\/10.1016\/j.ypmed.2024.108046","relation":{},"ISSN":["0091-7435"],"issn-type":[{"value":"0091-7435","type":"print"}],"subject":[],"published":{"date-parts":[[2024,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Patterns of gabapentinoid use among long-term opioid users","name":"articletitle","label":"Article Title"},{"value":"Preventive Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ypmed.2024.108046","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"108046"}}